

Resource Summary Report

Generated by SPARC SAWG on Aug 19, 2026

CD19 Antibody, anti-human, APC-Vio® 770, REAfinity™

RRID:AB_2726196

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-643, RRID:AB_2726196

Antibody Information

URL: http://antibodyregistry.org/AB_2726196

Proper Citation: Miltenyi Biotec Cat# 130-113-643, RRID:AB_2726196

Target Antigen: CD19

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-110-252. (RRID:AB_2655815).

Antibody Name: CD19 Antibody, anti-human, APC-Vio® 770, REAfinity™

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: clone REA675

Antibody ID: AB_2726196

Vendor: Miltenyi Biotec

Catalog Number: 130-113-643

Record Creation Time: 20250820T070842+0000

Record Last Update: 20250821T014150+0000

Ratings and Alerts

No rating or validation information has been found for CD19 Antibody, anti-human, APC-Vio® 770, REAfinity™.

No alerts have been found for CD19 Antibody, anti-human, APC-Vio® 770, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

David M, et al. (2025) Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs. Molecular therapy. Oncology, 33(2), 200989.

Piccinini C, et al. (2024) In vitro CAR-T cell killing: validation of the potency assay. Cancer immunology, immunotherapy : CII, 73(9), 168.

Giraud J, et al. (2024) THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1. Cell reports, 43(2), 113773.